Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation

It is not understood if dabigatran or rivaroxaban are superior to antiplatelet agents (AA) for safety outcomes in Asians with non-valvular atrial fibrillation (NVAF). In this study we evaluated the bleeding risk of dabigatran, rivaroxaban, warfarin and AA in Asians with NVAF. This national retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Yi-Hsin, Yeh, Yung-Hsin, Tu, Hui-Tzu, Kuo, Chi-Tai, Chang, Shang-Hung, Wu, Lung-Sheng, Lee, Hsin-Fu, See, Lai-Chu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716776/
https://www.ncbi.nlm.nih.gov/pubmed/29228736
http://dx.doi.org/10.18632/oncotarget.22026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716776/
https://www.ncbi.nlm.nih.gov/pubmed/29228736
http://dx.doi.org/10.18632/oncotarget.22026

Ejemplares similares